MARKET

TECH

TECH

Bio-Techne Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

365.32
+12.51
+3.55%
After Hours: 354.36 -10.96 -3.00% 16:03 05/26 EDT
OPEN
356.20
PREV CLOSE
352.81
HIGH
366.56
LOW
353.36
VOLUME
172.57K
TURNOVER
0
52 WEEK HIGH
543.85
52 WEEK LOW
334.71
MARKET CAP
14.33B
P/E (TTM)
66.64
1D
5D
1M
3M
1Y
5Y
Bio-Techne Announced Milerson 40,000 Unique RNAscope in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species
Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species.
Benzinga · 9h ago
What Is Bio-Techne Corporation's (NASDAQ:TECH) Share Price Doing?
Today we're going to take a look at the well-established Bio-Techne Corporation ( NASDAQ:TECH ). The company's stock...
Simply Wall St. · 1d ago
GLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHERESIS
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins. This publication rep...
PR Newswire · 1d ago
BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022, at 9:30 a.m. EDT. A live webcast of the presentation can b...
PR Newswire · 05/19 11:00
BRIEF-Bio-Techne And Nonagen Bioscience Announce Exclusive Supply Agreement For Nonagen's Oncuria Bladder Cancer Test
reuters.com · 05/12 11:13
Bio-Techne Reports Exclusive Supply Deal With Nonagen Bioscience For Nonagen's Oncuria Bladder Cancer Test, No Terms Disclosed
Techne Corporation (NASDAQ:TECH) and Nonagen Bioscience  today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer
Benzinga · 05/12 11:02
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test
Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology.
PR Newswire · 05/12 11:00
Bio-Techne Unit, Nonagen Bioscience Sign Manufacturing Deal for Oncuria Bladder Cancer Test
MT Newswires · 05/12 08:27
More
No Data
Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

45.45%Strong Buy
36.36%Buy
9.09%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average TECH stock price target is 509.90 with a high estimate of 595.00 and a low estimate of 370.00.
High595.00
Average509.90
Low370.00
Current 365.32
EPS
Actual
Estimate
0.541.071.612.14
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 691
Institutional Holdings: 42.14M
% Owned: 107.42%
Shares Outstanding: 39.23M
TypeInstitutionsShares
Increased
190
2.19M
New
59
940.30K
Decreased
199
2.07M
Sold Out
74
239.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Robert Baumgartner
President/Chief Executive Officer/Director
Charles Kummeth
Chief Financial Officer/Executive Vice President - Finance
James Hippel
Corporate Executive
William Geist
Corporate Executive
Kim Kelderman
Executive Vice President/General Counsel/Secretary
Brenda Furlow
Independent Director
Julie Bushman
Independent Director
John Higgins
Independent Director
Joseph Keegan
Independent Director
Roeland Nusse
Independent Director
Alpna Seth
Independent Director
Randolph Steer
Independent Director
Rupert Vessey
No Data
No Data
About TECH
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.